PMID- 33317355
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 1525-6073 (Electronic)
IS  - 0742-0528 (Linking)
VI  - 38
IP  - 3
DP  - 2021 Mar
TI  - Comparison of venlafaxine alone versus venlafaxine plus late partial sleep 
      deprivation therapy combination for major depressive disorder.
PG  - 378-386
LID - 10.1080/07420528.2020.1842753 [doi]
AB  - Treatment resistance, medication non-adherence, and side effects of 
      pharmacotherapeutics make treatment difficult in major depressive disorder. Sleep 
      deprivation is a fast-acting and tolerable reinforcement treatment method. In 
      this study, we investigated the effects of late partial sleep deprivation (PSD) 
      therapy added to venlafaxine treatment on symptoms of anxiety and depression, 
      sleep quality and treatment process. This study was conducted in a sample of 40 
      patients who were admitted to our inpatient psychiatric unit with a diagnosis of 
      major depressive disorder. While the venlafaxine (Ven) group received only 
      venlafaxine treatment, the venlafaxine+partial sleep deprivation (Ven+PSD) group 
      underwent late partial sleep deprivation therapy three times in the first week in 
      addition to venlafaxine treatment. The Hamilton Anxiety Rating Scale (HAM-A), 
      Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory, Pittsburgh 
      Sleep Quality Index, and Insomnia Severity Index (ISI) were administered to both 
      groups at the baseline and at the end of the 1st, 4th, and 6th weeks and, 
      additionally, Profile of Mood State (POMS) was administered to the Ven+PSD group 
      before and after each PSD. The Ven+PSD group had lower HAM-D and HAM-A scores 
      than the Ven group at the end of the 1st and 6th week. Both anxiety and 
      depression subscale scores on the POMS showed a significant decrease after PSD in 
      the Ven+PSD group. The mean venlafaxine dose (mg/d) was significantly lower in 
      the Ven+PSD group than in the Ven group. Late partial sleep deprivation is a 
      fast-acting and tolerable therapy in major depressive disorder.
FAU - Gunduz, Sule
AU  - Gunduz S
AD  - Department of Psychiatry, Ilgin State Hospital, Konya, Turkey.
FAU - Kandeger, Ali
AU  - Kandeger A
AUID- ORCID: 0000-0001-6940-0940
AD  - Department of Psychiatry, Faculty of Medicine, Selcuk University, Konya, Turkey.
FAU - Selvi, Yavuz
AU  - Selvi Y
AUID- ORCID: 0000-0003-0218-6796
AD  - Department of Psychiatry, Faculty of Medicine, Selcuk University, Konya, Turkey.
AD  - Neuroscience Research Center (SAM), Selcuk University, Konya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - 0 (Cyclohexanols)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
SB  - IM
MH  - Circadian Rhythm
MH  - Cyclohexanols/therapeutic use
MH  - *Depressive Disorder, Major/drug therapy
MH  - Humans
MH  - Psychiatric Status Rating Scales
MH  - Sleep Deprivation
MH  - Treatment Outcome
MH  - Venlafaxine Hydrochloride/therapeutic use
OTO - NOTNLM
OT  - anxiety
OT  - depression
OT  - partial sleep deprivation
OT  - treatment
OT  - venlafaxine
EDAT- 2020/12/16 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/12/15 05:38
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/12/15 05:38 [entrez]
AID - 10.1080/07420528.2020.1842753 [doi]
PST - ppublish
SO  - Chronobiol Int. 2021 Mar;38(3):378-386. doi: 10.1080/07420528.2020.1842753. Epub 
      2020 Dec 14.